Jurgi Camblong Sells 20,000 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) Chairman Jurgi Camblong sold 20,000 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $7.23, for a total transaction of $144,600.00. Following the completion of the sale, the chairman directly owned 3,452,822 shares in the company, valued at approximately $24,963,903.06. This represents a 0.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jurgi Camblong also recently made the following trade(s):

• On Monday, August 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.61, for a total transaction of $64,685.00.
• On Tuesday, August 4th, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.92, for a total transaction of $138,400.00.
• On Tuesday, July 21st, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.63, for a total transaction of $132,600.00.
• On Monday, July 20th, Jurgi Camblong sold 24,381 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.29, for a total value of $153,356.49.
• On Friday, July 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.62, for a total value of $47,770.00.
• On Tuesday, July 7th, Jurgi Camblong sold 17,685 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.28, for a total value of $93,376.80.
• On Monday, July 6th, Jurgi Camblong sold 22,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.25, for a total value of $118,051.50.
• On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total value of $7,826.10.
• On Friday, June 26th, Jurgi Camblong sold 50,069 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.80, for a total value of $290,400.20.
• On Wednesday, June 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.24, for a total value of $44,540.00.

SOPHiA GENETICS Price Performance

Shares of NASDAQ SOPH opened at $7.61 on Wednesday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. SOPHiA GENETICS SA has a fifty-two week low of $2.97 and a fifty-two week high of $7.88. The firm has a market capitalization of $638.40 million, a PE ratio of -6.62 and a beta of 0.96. The stock’s 50-day simple moving average is $5.73 and its 200-day simple moving average is $5.18.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The business had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. As a group, equities research analysts forecast that SOPHiA GENETICS SA will post -0.77 EPS for the current fiscal year.

SOPHiA GENETICS News Summary

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: BTIG Research raised its price target from $8 to $9 and HC Wainwright increased its target from $12 to $14; both firms maintained Buy ratings. The consensus target is approximately $10, suggesting potential upside from recent levels. SOPHiA GENETICS insider trading and analyst coverage
• Positive Sentiment: SOPHiA GENETICS reached a new one-year high, reflecting strong momentum after shares advanced substantially from their 52-week low of roughly $3. SOPHiA GENETICS reaches new one-year high
• Neutral Sentiment: Short interest was reported at zero shares, indicating no measurable short-selling pressure, although the reported comparison contained an invalid percentage change. The Q2 2026 earnings-call transcript was also released, but no additional quantified catalyst was provided in the available report. SOPHiA GENETICS Q2 2026 earnings call transcript
• Negative Sentiment: Chairman Jurgi Camblong sold a combined 28,500 shares for approximately $209,285, while CTO Abhimanyu Verma sold 5,000 shares for $38,000. Both transactions were conducted under pre-arranged Rule 10b5-1 plans, reducing their negative signaling, and both executives retained substantial positions. SOPHiA GENETICS insider sales
• Negative Sentiment: The latest quarter showed an adjusted loss of $0.26 per share versus the $0.21 consensus estimate, despite revenue of $23.31 million exceeding expectations. SOPHiA GENETICS remains unprofitable, with analysts forecasting a full-year loss of $0.77 per share.

Analysts Set New Price Targets

A number of research firms recently commented on SOPH. Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. BTIG Research raised their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Finally, HC Wainwright lifted their target price on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $10.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. First Dallas Securities Inc. purchased a new stake in shares of SOPHiA GENETICS in the first quarter valued at about $50,000. Squarepoint Ops LLC purchased a new position in shares of SOPHiA GENETICS during the third quarter worth about $49,000. Perkins Capital Management Inc. acquired a new position in SOPHiA GENETICS in the 4th quarter valued at about $49,000. Quadrature Capital Ltd acquired a new position in SOPHiA GENETICS in the 4th quarter valued at about $54,000. Finally, XTX Topco Ltd purchased a new stake in SOPHiA GENETICS during the 4th quarter valued at approximately $55,000. 31.59% of the stock is owned by hedge funds and other institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.